Exactech Investor Presentation Q1 2015

INVESTOR UPDATE1Q | 2015

KEY TO OUR SUCCESSExactech sustains a customer centric culture

that creates customer loyalty

Investment Highlights

Targeting $46 billion global biomedical device market

Consistent long term growth 2x as fast as overall market

Broad product portfolio of innovative products

Robust product pipeline expanding company’s market

Highly experienced orthopaedic management team

Growing sales organization with increasing rep productivity

Proven track record of creating long-term profitable growth

Our story.

• Surgeon founded

• Innovation to improve patient

outcomes

• Surgeon input driven

• Mainline & niche success

• Collaborative relationship with

sales force

• Financial stability

0

50

100

150

200

250

300

1985 1990 1994 1998 2002 2006 2010 2014

Proven track record of growth. (annual sales $ mil)

2010Vertical Supply

Acquisitions

2008

Entered Spine

Market2005

Equinoxe® Shoulder Launch

2001First Bone

Cement Sales

1998Entered Biologics Market

Internal Manufacturing

1996IPO

1994FirstKnee

ImplantSales

1985ExactechFounded

2008

French Distributor Acquisition

2010-12Expanded

OUS Direct Operations

2014Launch of

ExactechGPS®

CAS Technology Acquisition

Source: OrthoWorld Orthopaedic Industry Annual Report 2015

Targeting Highly Attractive Markets

0 2 4 6 8 10 120

2

4

6

8

10

Knee

Hip

Extr

Spine

Biologics

2014 Growth Rates

2014

S

ales

($B

illi

on

)

2014 sales by product line based on 2014 SEC 10-K

Broad Portfolio of Innovative Products2014 Sales by Business Unit ($ millions)

Extremities $79.032%

Other $23.49%

Knee $78.732%

Hip $43.517%

Bio-Spine $23.810%

Optetrak® Logic Knee System

• 30-year evolved design

• Streamlined instrumentation

• Multiple constraint options for

primary & revision knees with

NCM poly

• ExactechGPS®

Comprehensive total knee system with excellent clinical results.

ExactechGPS®

• Implant alignment accuracy

& precision

• Ease of use, cost-effective

• Surgeon maintains

operating control

• Competitive marketing edge

for hospitals

Guided, personalized surgery provides an effective solution to unmet needs

Portfolio PipelineExactech Knee

Concept Design & Development Limited Launch Full Launch Brand Maintenance

Adv. Ligament Balancing

GPSUni

Application

Logic Uni

AsymmetricPatella

LogicPorous

Tibia

Logic CC

GPSCC

Application

Logic RBK (US)

GPS v2

Logic CR Porous

Logic PS Porous

GPS

Logic PSC

Logic CRC

Logic PS

Logic CR

Logic FIT FBK

Cemented

Logic Fit RBK

Cemented

Optetrak PS/CR/R

BK

Optetrak CC

1H’152H’152016

Extremities

• Comprehensive platform

system

• Embraces the Glenoid with

unique bone-conserving

solutions

• Pipeline of strong clinical

publications

Equinoxe® Platform Shoulder redefining intra-operative flexibility, solving clinical challenges surgeons face

Portfolio PipelineExactech Extremities

Low Cost Shoulder

Muscle Augments

GPS Shoulder

Short/ Stemless Shoulder

Upgraded/ Ceramic

Glenosphere

Revision/Tumor Humeral Stem

Total Ankle

Cuff Sparing Instruments

Cage/ Augmented

Glenoid

Resurfacing Humeral

Head

CTA HH

Augmented Reverse Shoulder

Proximal Fx Plate

Cage Glenoid

Post Aug Glenoid

Platform Fx Stem

ReverseShoulder

Primary Shoulder

UHMWPE Glenoids

Humeral Heads

Original Fx Stem


2016 2H’15 1H’15

Hip

• Alteon® tapered wedge and Neck

Preserving stem designs

• Direct anterior approach

instrumentation

• Acetabular cup with InteGrip®

technology

Addressing the major philosophies of THA

Portfolio PipelineExactech Hip

Alteon Platform

Acetabular SysAlteon

HA

Alteon Revision Modular

Alteon Revision

MonoblockUniversal

Cup EMEA

Alteon Wedge

Alteon Neck Preserving

Novation Primary Femoral

InteGrip Cup

Element Femoral

GXL Cup

Crown Cup

AcuMatchFemoral

AcuMatchCup


2016 2H’15 1H’15

Biologics

• Optecure® / Opteform®

Allograft DBM products

• Accelerate® Cell Therapy

• Cartilage repair technology

under development

Innovative, clinically effective biomaterials

Portfolio PipelineExactech Biologics

BiCRI

Allograft Cartilage

Graft Delivery System

Reveille (Mincer)

Pure PRP

Tenomend

Ossigen

Accelerate PRP Sport

Optecure and Optcure CCC

Accelerate PRP

Opteform frozen

Opteform and Optefil RT

OpteMX*

*Distributed Product


Cement

• Cemex® bone cement

• InterSpace® pre-formed hip, knee

and shoulder spacers

• InterSpace® high release

Safety, simplicity and efficacy

Portfolio PipelineExactech Cement


Low CostCement

InterSpaceModular

Knee

InterSpaceFlat Hip

AcuDriver

CemexSystem

InterSpaceKnee

CemexManual

InterSpaceHip

InterspaceShoulder

Spine

• Proliant® pedicle screw system;

Silverbolt® MIS screw system

• Octane® PEEK cervical interbody;

Gibralt® posterior cervical

• Octane® Lumbar Interbody;

Expandable PEEK interbody

Expanding portfolio of spinal innovations

Portfolio PipelineExactech Spine

Design & Development Limited Launch Full Launch Brand Maintenance

Gibralt Line Ext.

Acapella One

Octane Straight Ti-coating

Octane MSilverbolt 2

Gibralt Occipital

Proliant Line Ext

Cervical Plate

Cervical Interbody

Silverbolt Octane T, P

Octane Straight

Proliant

Gibralt

Hydralok

Synergent DBM

2016 2H’15 1H’15

Exactech manufacturing

• Focused on U.S. manufacturing

• Up to 80% in-house

• Controlling costs to offset pricing

pressures and expand margins

Distributors

Global Offices

Manufacturing locations

Subsidiaries & HQ

USA

US

Network of independent sales agencies

Managed by corporate regional vice presidents

OUS

Network of independent distributors and wholly-owned subsidiaries

Direct operations in: Canada, UK, Spain, Germany, France, Japan, China

Our reach.

205

224

237

248 251

100

160

220

280

11 12 13 14 15G

Revenues ($ Mil)

FY Guidance$248-254MM; 0-3% increase;

3-6% constant currency

0.67

0.96

1.12

1.181.21

0.50

0.70

0.90

1.10

1.30

11 12 13 14 15G

EarningsPer Share

FY’15 Guidance

$1.18-1.24

Financial Trends

$ and shares in millions Mar- 15 Dec-14

Cash $12.3 $10.1

Debt $22.5 $23.3

Shareholders’ Equity $213.7 $211.4

Common Shares Outstanding (1) 14.2

Market Value (2) $293.5

(1) Fully diluted shares as reported in 5.7.15 10-Q(2) Share price of $20.98 as of 5.15.15 close

Summary Financial Data

Consistency in leadership.

• 30+ years average

industry experience

• 25 years average tenure

with Exactech

Founders and Officers

2015 Initiatives

Sustain momentum in Extremities- glenoid / augment launch

Return to above market Knee / Hip growth

Continue launches of organic spinal products

ExactechGPS (Guided Personalized Surgery) Knee

Alteon™ Hip system launch

Major new Knee & Hip Revision launches

Continue cash flow results from lean supply chain initiatives

Leverage opportunities to acquire seasoned sales agents due to market disruption

Why Exactech.

• Culture, agent relationships &

surgeon leadership

• Understanding of market needs

• Patient-driven innovations &

robust product pipeline

• Proven financial performance

and corporate stability

Thank you.

Exactech Investor Presentation Q1 2015

Investor Relations

Transcript of Exactech Investor Presentation Q1 2015